ONY BIOTECH PREPARES FOR THE FUTURE
May 19, 2020 | Company
Dr. James Cummings has been an unofficial member of the ONY Biotech family since 1989, when he first started working at the Children’s Hospital of Buffalo.
This month, it becomes official, as Dr. Cummings joins the ONY Biotech team as Chief Medical Officer, and the founder of the company and former Chief Medical Officer, Dr. Edmund Egan, steps into the role of Chief Scientific Officer.
“Back in 1989, two things struck me from the start,” Cummings said,
“One was that ONY had an incredible new product [Infasurf®] that would transform neonatal intensive care. The other was their company was all about caring—caring for critically ill preterm infants, caring for the providers who treat those infants, and caring for the people who make up ONY.”
Most recently, Dr. Cummings, who earned his medical degree and completed his residency at the State University of New York’s Upstate Medical Center in Syracuse, New York, served as a Professor of Pediatrics and Bioethics at Albany Medical Center in the Capital Region.
Prior to moving to Albany in 2012, Dr. Cummings was the Section Head of Neonatology and Director for the Neonatal-Perinatal Medicine Fellowship Program at East Carolina University in Greenville, North Carolina, for more than 15 years.
“The addition of Dr. Cummings provides us with enhanced clinical research capability immediately—and for the future,” Dr. Egan said. “My evolution from Chief Medical Officer to Chief Scientific Officer will allow us to expand my efforts on the pre-clinical research projects at ONY, while Dr. Cummings’ research achievements and national stature in neonatal-perinatal medicine make him the ideal person to lead our medical efforts.”
President and CEO of ONY Biotech, Randy Burkard, echoed Dr. Egan’s sentiments.
“We’ve known Dr. Cummings for a long time, and there’s no doubt in my mind that—in addition to his long list of accomplishments—he is someone who embodies the ONY way: dedicated and determined; deeply invested in the families whose lives we have the potential to change for the better; and most of all—persistent in our shared pursuit to develop less invasive ways to treat premature babies.”
Back to news